Literature DB >> 22593491

Methodological and preanalytical evaluation of a RAGE immunoassay.

Christin Wittwer1, Julia Lehner, Debora Fersching, Barbara Siegele, Oliver J Stoetzer, Stefan Holdenrieder.   

Abstract

BACKGROUND: Soluble receptor of advanced glycation end products (sRAGE) is a promising biomarker for the prognosis and the monitoring of cancer and of acute diseases such as trauma and sepsis.
MATERIALS AND METHODS: We investigated the methodological characteristics of an ELISA for sRAGE (R&D Diagnostics) including intra- and inter-assay imprecision, dilution linearity and differences in various serum and plasma materials. Furthermore, the influence of various preanalytical factors such as time and storage temperature before and after centrifugation prior to definite deep freezing, as well as multiple freeze-thaw cycles, were tested. By the use of sera from 30 healthy individuals, a reference range and the dependency on patient characteristics was established.
RESULTS: Intra-assay imprecision (coefficients of variation (CV): 6.0-11.5%) and inter-assay imprecision (5.9-7.8%) were in an acceptable range of manual assays. Linearity testing yielded satisfying results with dilution recoveries of 99-131%. Results of serum, EDTA-plasma (recovery of 85.9-114.7%), and heparin-plasma samples (88-102%) were quite comparable, while results from citrate-plasma were slightly lower (78-96%). There was no influence of the time to centrifugation after 6 and 24 hours (recoveries 87-102%) at storage temperatures of 4°C and 25°C. Similarly, results were the same when samples were kept at 4°C and 25°C after centrifugation for up to 7 days (recoveries 88-109%). Repeated freeze-thawing of samples did not affect the results obtained for the RAGE protein (recoveries 92-104%). The median value of healthy individuals was 1.10 ng/ml, with 90% limits of 0.52 to 1.49 ng/ml.
CONCLUSION: sRAGE ELISA is a very robust and safe assay which produces reliable quantitative results for sera and plasma measurements.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593491

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.

Authors:  Casey M Rebholz; Brad C Astor; Morgan E Grams; Marc K Halushka; Mariana Lazo; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Elizabeth Selvin
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

2.  Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve and associated aortopathies.

Authors:  Emanuela Branchetti; Joseph E Bavaria; Juan B Grau; Richard E Shaw; Paolo Poggio; Eric K Lai; Nimesh D Desai; Joseph H Gorman; Robert C Gorman; Giovanni Ferrari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-14       Impact factor: 8.311

3.  Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-11

4.  Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.

Authors:  Oliver J Stoetzer; Debora M I Fersching; Christoph Salat; Oliver Steinkohl; Christian J Gabka; Ulrich Hamann; Michael Braun; Axel-Mario Feller; Volker Heinemann; Barbara Siegele; Dorothea Nagel; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-15

5.  Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE).

Authors:  Julie K Bower; James S Pankow; Mariana Lazo; Eric Christenson; Ron C Hoogeveen; Christie M Ballantyne; Marc K Halushka; Brad C Astor; Elizabeth Selvin
Journal:  Clin Biochem       Date:  2013-11-15       Impact factor: 3.281

Review 6.  The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes.

Authors:  Jorge D Erusalimsky
Journal:  Redox Biol       Date:  2021-03-29       Impact factor: 11.799

Review 7.  Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.

Authors:  Christin Pilzweger; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2015-06-16

8.  sRAGE and risk of diabetes, cardiovascular disease, and death.

Authors:  Elizabeth Selvin; Marc K Halushka; Andreea M Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Diabetes       Date:  2013-02-08       Impact factor: 9.461

Review 9.  Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome.

Authors:  Louise J N Jensen; Allan Flyvbjerg; Mette Bjerre
Journal:  Biomed Res Int       Date:  2015-09-30       Impact factor: 3.411

10.  Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients.

Authors:  Tarek Mk Motawi; Mohamed A Abou-Seif; Ahmed Ma Bader; Mohamed O Mahmoud
Journal:  BMC Endocr Disord       Date:  2013-08-21       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.